•   
  •   
  •   

Politics AstraZeneca vaccine distribution begins in Brazil

07:18  24 january  2021
07:18  24 january  2021 Source:   thehill.com

Philippines Approves Pfizer Shots; New Korea Cases: Virus Update

  Philippines Approves Pfizer Shots; New Korea Cases: Virus Update The Philippines approved Pfizer Inc.-BioNTech SE’s vaccine, the first to be allowed for emergency use in the country. Australia defended its use of the AstraZeneca vaccine. © Bloomberg A healthcare worker prepares a dose of the AstraZeneca Plc and the University of Oxford Covid-19 vaccine in the mass vaccination center set-up at the Epsom Downs racecourse in Epsom, U.K., on Monday, Jan. 11, 2021. China recorded its first Covid-19 death since April as new clusters continued to expand.

Brazil began distributing close to 2 million doses of the AstraZeneca coronavirus vaccine on Saturday, Brazilian health officials announced.

Brazil has the world's second-highest Covid death toll but has seen delay and discord over vaccines . Regulator Anvisa gave the green light to vaccines from Oxford- AstraZeneca and China's Sinovac, doses of which will The far-right leader has played down the pandemic from the beginning

Brazil began distributing close to 2 million doses of the AstraZeneca coronavirus vaccine on Saturday, Brazilian health officials announced.

a close up of a bottle: AstraZeneca vaccine distribution begins in Brazil © Getty Images AstraZeneca vaccine distribution begins in Brazil

According to Reuters, Brazil's federally funded Fiocruz Institute said it had begun distribution of the vaccine after the doses arrived from India on Friday.

While Brazil's government currently has a deal with AstraZeneca to produce up to 100 million doses of its vaccine locally, the country has recently faced delays from China in the delivery of the active ingredient needed to produce the vaccine.

Brazil weighs COVID-19 vaccines as its death toll climbs

  Brazil weighs COVID-19 vaccines as its death toll climbs ​​​​​​​Brazil’s health regulatory agency Anvisa has yet to approve a vaccine, but the directors are expected to meet this Sunday to vote on both the CoronaVac and AstraZeneca vaccines. This week, it was announced that the efficacy of Brazil’s top COVID-19 vaccine, CoronaVac, was only just over 50%. The week before, it had been reported that it was close to 80%.The news made international headlines. Both Reuters and The New York Times called the results “disappointing.”But during a two-hour press conference, researchers and members of the São Paulo health institute Butantan, and the São Paulo state government pushed back.

Brazil 's National Health Surveillance Agency (Anvisa) suspended the trial on Monday after an China's Sinovac began Phase 3 clinical trials of its CoronaVac vaccine in collaboration with the In September, drug giant AstraZeneca paused global trials of its coronavirus vaccine because of an

Trials of a Covid-19 vaccine being developed by AstraZeneca and Oxford University will continue, following a review into the death of a volunteer in Brazil . Brazil 's health authority has given no details about the death, citing confidentiality protocols. Oxford University said a "careful assessment" had

AstraZeneca agreed to give Brazil 2 million ready-to-use doses made in India in order for the government to start distributing the vaccine to its citizens, Reuters reported.


Video: Vaccinations start as Brazil faces shortages (Reuters)

The distribution comes as Brazil thus far has relied on the Chinese Sinovac vaccine, which health officials in Brazil last week said is just over 50 percent effective at preventing COVID-19, an efficacy rate that is much lower than the 78 percent officials in São Paulo previously estimated.

However, São Paulo's Butantan Institute maintains that the Chinese inoculation remains 100 percent effective at preventing "severe" or "moderate" coronavirus infections, while mild or very mild infections remain possible after receiving the shot.

India is launching one of the world’s largest vaccination campaigns. But it’s unclear if one of the vaccines works.

  India is launching one of the world’s largest vaccination campaigns. But it’s unclear if one of the vaccines works. India is rolling out two locally made vaccines but only one has completed a Phase 3 trial. India is set to launch on Saturday one of the world’s largest vaccination campaigns with the aim of immunizing 300 million people by this summer.

Brazilian health authority Anvisa said on Wednesday that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and Oxford University had died but added that the trial would continue. Oxford confirmed the plan to keep testing, saying in a statement that after careful

AstraZeneca has been granted protection from future product liability claims related to its COVID-19 vaccine hopeful by most With 25 companies testing their vaccine candidates on humans and getting ready to immunise hundred millions of people once the products are shown to work, the question of

Brazil has had the second highest number of COVID-19 deaths in the world, with more than 216,000 as of Saturday, according to data compiled by Johns Hopkins University. The South American country is also in third place for total infections, with more than 8.8 million reported.

The United Kingdom earlier this month became the first country to begin administering the AstraZeneca vaccine, which was developed through a partnership with Oxford University. India and Pakistan have also since approved the inoculation for use.

Trial data revealed the AstraZeneca vaccine to have a 62 percent efficacy rate if given in two full doses 28 days apart as it was for most participants. However, the vaccine was found to be 90 percent effective when a small group in the trial was mistakenly given half a dose initially followed by a full dose.

Given the questions surrounding the trial data, U.S. health experts initially predicted it would take months to receive emergency approval for AstraZeneca's vaccine, though Anthony Fauci, the nation's top infectious disease expert, said last week that approval of the shot, as well as one from Johnson & Johnson, was likely "weeks away."

The Haute Autorité de Santé does not recommend the AstraZeneca vaccine for people over 65 .
© Copyright 2021, L'Obs Can the vaccine manufactured by AstraZeneca be injected into the elderly? The Haute Autorité de Santé (HAS) answered no to this question on Tuesday, February 2 during a press conference, by not recommending its use for people over 65. On this response, eagerly awaited, depended on the continuation of the vaccine campaign in France against Covid-19, which continues to weigh on hospitals.

usr: 0
This is interesting!